Experiment 1027095
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | ROUESSE,J: HUERTAS,D: SANCHO-GARNIER,H: LE CHEVALIER,T: AMIEL,JL: BRULE,G: TURSZ,T: MONDESIR,JM:. (1981). 2 N METHYL 9 HYDROXY-ELLIPTICINE IN TREATMENT OF METASTATIC BREAST CANCERS.. 68() |
| Amount utilized | |
| Compound isolated | |
| Disease | A PHASE II CLINICAL TRIAL IN 57 PATIENTS WITH ADVANCED METASTATIC BREAST CANCER. DOSING WAS ONCE WEEKLY. EVALUATION OF RESPONSE, AFTER AT LEAST 4 INJECTIONS, WAS POSSIBLE IN 46 PATIENTS. TWO COMPLETE REGRESSIONS (OF 3 AND 12 MONTHS) AND 7 REGRESSIONS OF OVER 50% WERE OBSERVED, A TOTAL REGRESSION RATE OF 19%. REGRESSION WAS MAINLY OBSERVED IN CUTANEOUS OR SUBCUTANEOUS METASTASES. NO OBJECTIVE REGRESSION WAS NOTED FOR PULMONARY OR HEPATIC METASTASES. BONE METASTASES WERE NOT TAKEN INTO ACCOUNT WHEN ASSESSING RESPONSE TO TREATMENT. ABSENCE OF HEMATOLOGICAL CHANGES WAS NOTED. THE MOST FREQUENT SIDE EFFECTS WERE ANOREXIA,NAUSEA,VOMITING AND DRYNESS OF MOUTH. MAJOR TOXICITY WAS INTRAVASCULAR HEMOLYSIS (6/175 PATIENTS). A LACK OF MYELOTOXICITY WAS CONSIDERED OF MAJOR IMPORTANCE FOR FUTURE CONSIDERATION. |
| Dose amount | 100.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |
| Gender | FEMALE |